Gelteq Limited focuses on developing, testing, and commercializing white label gel-based delivery solutions for humans and animals in Asia-Pacific Region. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. The company has a strategic alliance with IDT Australia Limited for the development and scale up of its gel-based products across diverse global pharmaceutical, nutraceutical and animal health markets and has a strategic alliance with Melbourne Health for the development of maize starch butyrylated, or HAMSB, a compound with the potential to reduce bowel polyp growth which could lower the risk of bowel cancer. Gelteq Limited was incorporated in 2017 and is headquartered in Caulfield, Australia.
Metrics to compare | GELS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGELSPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.7x | −1.0x | −0.7x | |
PEG Ratio | - | 0.01 | 0.00 | |
Price/Book | 1.0x | 1.2x | 2.6x | |
Price / LTM Sales | 51.2x | 3.4x | 3.4x | |
Upside (Analyst Target) | - | 0.0% | 37.9% | |
Fair Value Upside | Unlock | −5.2% | 5.2% | Unlock |